Inflammatory molecules circulating in the blood may worsen disease symptoms and points to new opportunities for targeted therapy.
Promising Biomarker Reductions: Treatment with the MDM2 inhibitor navtemadlin led to significant reductions in key biomarkers of disease severity, including circulating CD34+ cells, a hallmark of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback